Francesca De Felice1, Christopher Thomas2, Vinod Patel3, Steve Connor4, Andriana Michaelidou4, Chris Sproat3, Jerry Kwok3, Mary Burke5, Damien Reilly5, Mark McGurk6, Ricard Simo6, Andrew Lyons6, Richard Oakley6, Jean-Pierre Jeannon6, Mary Lei4, Teresa Guerrero Urbano7. 1. Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK; Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. 2. Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London, UK. 3. Oral Surgery Department, Guy's and St Thomas' NHS Foundation Trust, London, UK. 4. Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 5. Department of Sedation and Special Care Dentistry, Guy's and St Thomas' NHS Foundation Trust, London, UK. 6. Head and Neck Cancer Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK. 7. Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: teresa.guerrerourbano@gstt.nhs.uk.
Abstract
OBJECTIVES: To analyze clinical features, dosimetric parameters, and outcomes of osteoradionecrosis (ORN). STUDY DESIGN: Thirty-six patients with ORN who had been previously treated with radiotherapy (RT) were retrospectively identified between January 2009 and April 2014. ORN volumes were contoured on planning computed tomography (CT) scans. Near maximum dose (D2%), minimum dose (Dmin), mean dose (Dmean), and percentage of bone volume receiving 50 Gy (V50) were examined. Clinical and dosimetric variables were considered to compare ORN resolution versus ORN persistence. RESULTS: Median interval time from end of RT to development of ORN was 6 months. Of the ORN cases, 61% were located in the mandible. Dmean to affected bone was 57.6 Gy, and 44% had a D2% 65 Gy or greater. Smoking was associated with ORN persistence on univariate analysis, but no factors were found to impact ORN resolution or progression on logistic regression. CONCLUSIONS: Prevention strategies for ORN development should be prioritized. Dose-volume parameters could have a role in preventing ORN.
OBJECTIVES: To analyze clinical features, dosimetric parameters, and outcomes of osteoradionecrosis (ORN). STUDY DESIGN: Thirty-six patients with ORN who had been previously treated with radiotherapy (RT) were retrospectively identified between January 2009 and April 2014. ORN volumes were contoured on planning computed tomography (CT) scans. Near maximum dose (D2%), minimum dose (Dmin), mean dose (Dmean), and percentage of bone volume receiving 50 Gy (V50) were examined. Clinical and dosimetric variables were considered to compare ORN resolution versus ORN persistence. RESULTS: Median interval time from end of RT to development of ORN was 6 months. Of the ORN cases, 61% were located in the mandible. Dmean to affected bone was 57.6 Gy, and 44% had a D2% 65 Gy or greater. Smoking was associated with ORN persistence on univariate analysis, but no factors were found to impact ORN resolution or progression on logistic regression. CONCLUSIONS: Prevention strategies for ORN development should be prioritized. Dose-volume parameters could have a role in preventing ORN.
Authors: F De Felice; V Tombolini; M de Vincentiis; G Magliulo; A Greco; V Valentini; A Polimeni Journal: Med Oncol Date: 2018-11-13 Impact factor: 3.064
Authors: Angela T T Wong; Stephen Y Lai; G Brandon Gunn; Beth M Beadle; Clifton D Fuller; Martha P Barrow; Theresa M Hofstede; Mark S Chambers; Erich M Sturgis; Abdallah Sherif Radwan Mohamed; Jan S Lewin; Katherine A Hutcheson Journal: Oral Oncol Date: 2017-01-21 Impact factor: 5.337
Authors: John M Hoyle; Tanya A Correya; Kelly Kenzik; Liton Francisco; Sharon A Spencer; Christopher D Willey; James A Bonner; James W Snider; Drexell Hunter Boggs; William R Carroll; Smita Bhatia; Andrew M McDonald Journal: Head Neck Date: 2022-01-25 Impact factor: 3.147